HeartSciences Inc. (HSCS) intrinsic value & 10-year financials
HeartSciences Inc. (HSCS) has a Graham intrinsic value of $364.99 per share. At $3.02 on Oct 17, 2026, the stock trades 99% below that value. Over the last 6 fiscal years revenue shrank 26.0% a year to $4.3K, with an average return on invested capital of 168.8%.
- Graham intrinsic value
- $364.99
- Share price (Oct 17, 2026)
- $3.02
- Price vs Graham value
- 99% below
- Market cap
- $2.8M
- Revenue (FY2026)
- $4.3K
- Revenue growth (6-yr CAGR)
- -26.0%
- ROIC (10-yr avg)
- 168.8%
- Free cash flow (FY2026)
- -$7.4M
HSCS 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2026 | $4.3K | -$9.1M | — | -$7.4M | -194787.4% | -391.6% |
| FY2025 | $4.3K | -$8.8M | -$9.34 | -$7.4M | -192013.1% | -378.2% |
| FY2024 | $18.6K | -$6.6M | -$19.00 | -$6.1M | -33902.0% | -518.0% |
| FY2023 | $5.2K | -$6.4M | -$0.80 | -$5.8M | -118698.3% | 1596.9% |
| FY2022 | $14.4K | -$4.8M | -$1.45 | -$3.6M | -32765.6% | 535.1% |
| FY2021 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
HeartSciences Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
HeartSciences Inc. has historically struggled to out-earn its cost of capital, averaging just 1.7% ROIC.
HeartSciences Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, HeartSciences Inc. is modeled at -26.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $364.99 per share.